|
Discovery | Pre-Clinical | Phase I | Phase II | Phase III | Manufacturing |
Regulatory | EB Programs
Merck hosted its third Life Science Executive Summit on January 12, 2017.
The purpose of the event was to establish an open dialog within the biotech community and provide networking opportunities and insights from executives on venture funding, investment management and process development.
Read our white paper to get the key takeaways from the summit, including lessons learned on the road from concept to clinic, and how companies can fuel their vision.
View the agenda.
Unlock your molecule's potential
2018 Advance Biotech Grant ProgramBringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.
Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.
Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.
Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.
Establishing an open dialog within the biotech community....
A report from the The Economist Intelligence Unit sponsored by Merck.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.
Research. Development. Production.
We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.
